10:41 AM EST, 11/07/2024 (MT Newswires) -- Aurinia Pharmaceuticals ( AUPH ) shares were up more than 10% in recent trading Thursday after the company reported better-than-expected Q3 net income and revenue.

The company reported Q3 net income Thursday of $0.10 per diluted share, swinging from a net loss of $0.09 per share a year earlier.

Analysts polled by Capital IQ expected earnings of $0.02 per share.

Net revenue for the quarter ended Sept. 30 was $67.8 million, compared with $54.5 million a year earlier.

Analysts polled by Capital IQ expected $57.7 million.

The company said it will implement strategic restructuring, which includes reducing its workforce by about 45%, to focus on the commercial strategy for its Lupkynis treatment for lupus nephritis. This restructuring is estimated to yield over $40 million in annualized savings and $15 million to $19 million one-time charge in Q4.

Price: 8.33, Change: +0.81, Percent Change: +10.77